were created and treated with honokiol. Amounts of phosphorylated and non-phosphorylated Akt and mTOR in glioma tissues were analyzed to determine the possible mechanisms of honokiolinduced autophagy. 
Specifications Table

Subject area
Biology More specific subject area
Biological medicine
Type of data Images, figures How data was acquired
Raw data by immunoblotting assays Quantified data by statistical analyses Data format
Raw, quantified Experimental factors
Human glioma cells were cultured and treated with honokiol or chloroquine. Mice with glioma were created and treated with honokiol.
Experimental features
Proteins from human glioma cells and mouse glioma tissues were isolated and separated using SDS-PAGE. Immunoblotting analyses of autophagy-related proteins were carried out and protein bands were quantified and statistically analyzed.
Data source location
Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan; Brain Disease Research Center, Taipei Medical University Wan-Fang Hospital, Taipei, Taiwan Data accessibility All data are with this article.
Value of the data
These data are acquired from in vitro and in vivo models of human glioma and these models are helpful for drug discovery for brain tumors.
The present data provide several lines of evidence explaining if honokiol induced autophagic insults to human glioma cells.
These data validate the possible mechanisms illustrating how honokiol induced autophagy of human glioma cells.
Data
To elucidate the honokiol (HNK)-induced autophagic flux, human glioma cells were exposed to HNK, and levels of p62, a biomarker of autophagy, were analyzed ( Fig. 1A and B) . Chloroquine (CQ), a lysosomal inhibitor, was added into human glioma cells to confirm the HNK-induced cell autophagy ( Fig. 1C and D) . In addition, amounts of beclin-1, an upstream modulator of autophagy, in human glioma cells were further analyzed (Fig. 2 ). An intracranial model was established to test the effects of HNK on induction of autophagy in development of glioma by analyses of phosphorylated (p) and nonphosphorylated Akt and mTOR (Fig. 3 ).
Experimental design, materials and methods
Cell culture and drug treatment
Human U87 MG cells purchased from American Type Culture Collection (Manassas, VA, USA) were seeded in minimum essential medium (MEM, Gibco-BRL Life Technologies, Grand Island, NY, USA) [3] . The MEM was supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 IU/mL penicillin, 100 mg/mL streptomycin, 1 mM sodium pyruvate, and 1 mM nonessential amino acids. Human U87 MG cells were grown in a humidified atmosphere of 5% CO 2 at 37°C. Honokiol was purchased from Sigma (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide. Human U87 MG Cells were exposed to honokiol for different intervals. For the inhibition assays, the cells were pretreated with chloroquine, a lysosomal inhibitor, for 1 h and then treated with honokiol.
Animal orthotopic brain tumor model and drug treatment
An intracranial glioma model was created as described previously [1] . All procedures in this study were approved by the Institutional Animal Care and Use Committee of Taipei Medical University (Taipei, Taiwan). Briefly, female nude mice (BALB/c nu/nu) were purchased from the National Laboratory Animal Center, Taipei, Taiwan. Human U87 MG cells (2 Â 10 5 cells) were suspended in 3 ml phosphate-buffered saline and then stereotactically inoculated into the right frontal lobe using a syringe pump (SINGA Technology, Taipei, Taiwan). After implantation for 4 days, these glioma-bearing mice were intraperitoneally injected with 20 mg/kg honokiol or vehicle two times per week for 2 weeks. The animals were sacrificed following implantation of glioma cells for 3weeks. Brains were removed for further analyses. Gliomas were measured according to a previously described method [1] .
Immunoblotting
Human U87 MG cells or mouse brain tissues were lysed with an ice-cold lysis buffer (25 mM HEPES, 1.5% Triton X-100, 0.1% sodium dodecylsulfate (SDS), 0.5 M NaCl, 5 mM EDTA, and 0.1 mM sodium deoxycholate) as described previously [3, 4] . Proteins were separated using SDS-polyacrylamide gel electrophoresis and then transferred onto nitrocellulose membranes. After blocking with a 5% skim milk solution, the membranes were incubated with indicated antibodies against LC3, beclin-1, phosphorylated (p)-Akt, Akt, p-mTOR, and mTOR (Cell Signaling Technology (Beverly, MA, USA) and p62 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Membranes were probed with the appropriate secondary antibodies at room temperature. Those immunoreactive proteins were detected using an enhanced chemiluminescence reagent (Western Lightning of β-actin were immunodetected as the internal control (Sigma). The density of these protein bands were quantified using a digital analyzer [2] .
Statistical analysis
The statistical significance of differences between the control and drug-treated groups was evaluated using Student's t-test; differences between drug-treated groups were evaluated using Duncan's multiple-range test. Statistical analyses between groups over time were carried out by a two-way analysis of variance. A p value of o0.05 was considered statistically significant. Vehicle HNK * Fig. 3 . Immunoblotting analyses of phosphorylated (p) and non-phosphorylated Akt and mTOR in mouse glioma tissues. Mice with an intracranial glioma and administration of honokiol (HNK) were described in "Experimental design, materials and methods". After being sacrificed, mice brains were removed for immunoblotting analyses of Akt, p-Akt, mTOR, and p-mTOR (A and C). Levels of β-actin were analyzed as the internal control (B and D). Each value represents the mean 7SEM from three independent experiments. n Values significantly differed from the control group, p o 0.05.
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